Cargando…

The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(−/−) mice

Apolipoprotein J (APOJ) is a multifunctional protein with genetic evidence suggesting an association between APOJ polymorphisms and Alzheimer’s disease as well as exfoliation glaucoma. Herein we conducted ocular characterizations of Apoj(−/−) mice and found that their retinal cholesterol levels were...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Darzi, Nicole, Mast, Natalia, Li, Yong, Dailey, Brian, Kang, Min, Rhee, Douglas J., Pikuleva, Irina A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314885/
https://www.ncbi.nlm.nih.gov/pubmed/37392222
http://dx.doi.org/10.1007/s00018-023-04848-y
_version_ 1785067403145641984
author El-Darzi, Nicole
Mast, Natalia
Li, Yong
Dailey, Brian
Kang, Min
Rhee, Douglas J.
Pikuleva, Irina A.
author_facet El-Darzi, Nicole
Mast, Natalia
Li, Yong
Dailey, Brian
Kang, Min
Rhee, Douglas J.
Pikuleva, Irina A.
author_sort El-Darzi, Nicole
collection PubMed
description Apolipoprotein J (APOJ) is a multifunctional protein with genetic evidence suggesting an association between APOJ polymorphisms and Alzheimer’s disease as well as exfoliation glaucoma. Herein we conducted ocular characterizations of Apoj(−/−) mice and found that their retinal cholesterol levels were decreased and that this genotype had several risk factors for glaucoma: increased intraocular pressure and cup-to-disk ratio and impaired retinal ganglion cell (RGC) function. The latter was not due to RGC degeneration or activation of retinal Muller cells and microglia/macrophages. There was also a decrease in retinal levels of 24-hydroxycholesterol, a suggested neuroprotectant under glaucomatous conditions and a positive allosteric modulator of N-methyl-d-aspartate receptors mediating the light-evoked response of the RGC. Therefore, Apoj(−/−) mice were treated with low-dose efavirenz, an allosteric activator of CYP46A1 which converts cholesterol into 24-hydroxycholesterol. Efavirenz treatment increased retinal cholesterol and 24-hydroxycholesterol levels, normalized intraocular pressure and cup-to-disk ratio, and rescued in part RGC function. Retinal expression of Abcg1 (a cholesterol efflux transporter), Apoa1 (a constituent of lipoprotein particles), and Scarb1 (a lipoprotein particle receptor) was increased in EVF-treated Apoj(−/−) mice, indicating increased retinal cholesterol transport on lipoprotein particles. Ocular characterizations of Cyp46a1(−/−) mice supported the beneficial efavirenz treatment effects via CYP46A1 activation. The data obtained demonstrate an important APOJ role in retinal cholesterol homeostasis and link this apolipoprotein to the glaucoma risk factors and retinal 24-hydroxycholesterol production by CYP46A1. As the CYP46A1 activator efavirenz is an FDA-approved anti-HIV drug, our studies suggest a new therapeutic approach for treatment of glaucomatous conditions.
format Online
Article
Text
id pubmed-10314885
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-103148852023-07-03 The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(−/−) mice El-Darzi, Nicole Mast, Natalia Li, Yong Dailey, Brian Kang, Min Rhee, Douglas J. Pikuleva, Irina A. Cell Mol Life Sci Original Article Apolipoprotein J (APOJ) is a multifunctional protein with genetic evidence suggesting an association between APOJ polymorphisms and Alzheimer’s disease as well as exfoliation glaucoma. Herein we conducted ocular characterizations of Apoj(−/−) mice and found that their retinal cholesterol levels were decreased and that this genotype had several risk factors for glaucoma: increased intraocular pressure and cup-to-disk ratio and impaired retinal ganglion cell (RGC) function. The latter was not due to RGC degeneration or activation of retinal Muller cells and microglia/macrophages. There was also a decrease in retinal levels of 24-hydroxycholesterol, a suggested neuroprotectant under glaucomatous conditions and a positive allosteric modulator of N-methyl-d-aspartate receptors mediating the light-evoked response of the RGC. Therefore, Apoj(−/−) mice were treated with low-dose efavirenz, an allosteric activator of CYP46A1 which converts cholesterol into 24-hydroxycholesterol. Efavirenz treatment increased retinal cholesterol and 24-hydroxycholesterol levels, normalized intraocular pressure and cup-to-disk ratio, and rescued in part RGC function. Retinal expression of Abcg1 (a cholesterol efflux transporter), Apoa1 (a constituent of lipoprotein particles), and Scarb1 (a lipoprotein particle receptor) was increased in EVF-treated Apoj(−/−) mice, indicating increased retinal cholesterol transport on lipoprotein particles. Ocular characterizations of Cyp46a1(−/−) mice supported the beneficial efavirenz treatment effects via CYP46A1 activation. The data obtained demonstrate an important APOJ role in retinal cholesterol homeostasis and link this apolipoprotein to the glaucoma risk factors and retinal 24-hydroxycholesterol production by CYP46A1. As the CYP46A1 activator efavirenz is an FDA-approved anti-HIV drug, our studies suggest a new therapeutic approach for treatment of glaucomatous conditions. Springer International Publishing 2023-07-01 2023 /pmc/articles/PMC10314885/ /pubmed/37392222 http://dx.doi.org/10.1007/s00018-023-04848-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
El-Darzi, Nicole
Mast, Natalia
Li, Yong
Dailey, Brian
Kang, Min
Rhee, Douglas J.
Pikuleva, Irina A.
The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(−/−) mice
title The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(−/−) mice
title_full The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(−/−) mice
title_fullStr The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(−/−) mice
title_full_unstemmed The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(−/−) mice
title_short The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(−/−) mice
title_sort normalizing effects of the cyp46a1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in apoj(−/−) mice
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314885/
https://www.ncbi.nlm.nih.gov/pubmed/37392222
http://dx.doi.org/10.1007/s00018-023-04848-y
work_keys_str_mv AT eldarzinicole thenormalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT mastnatalia thenormalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT liyong thenormalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT daileybrian thenormalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT kangmin thenormalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT rheedouglasj thenormalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT pikulevairinaa thenormalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT eldarzinicole normalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT mastnatalia normalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT liyong normalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT daileybrian normalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT kangmin normalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT rheedouglasj normalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice
AT pikulevairinaa normalizingeffectsofthecyp46a1activatorefavirenzonretinalsterollevelsandriskfactorsforglaucomainapojmice